Orthopedic Medical Device Company A-de Technology Completes Hundreds of Millions RMB Series A Financing Led by Sinopharm Capital
AND
Orthopedic Medical Device R&D and Supplier
On March 28, 2019, VCBeat (WeChat ID: vcbeat) learned that AND had completed its first round of financing, amounting to hundreds of millions of yuan. The medical device equity investment fund under Sinopharm Capital led the round, with follow-on investments from Yida Capital and Jiale Capital. On the same day, the equity investment signing ceremony for “AND Introduces Strategic Shareholders” was grandly held in Shanghai. Attendees at the signing ceremony included Wu Aimin, President of Sinopharm Capital; Shi Shenghao, Managing Director of Sinopharm Capital; Xue Yi, Partner at Yida Capital; Ding Jiping, Partner at Jiale Capital; Lu Qiang, Chairman of AND; and Li Yifei, General Manager of AND.
Lu Qiang, founder of AND, stated: “To meet the company’s strategic development needs, we have optimized our equity structure and actively embraced capital markets by introducing three strategic investors, including Sinopharm Capital, through a capital increase and share expansion. This round of financing will have a positive and far-reaching impact on AND’s business development, brand enhancement, and future capitalization strategy from a strategic perspective.”
Meanwhile, Lu Qiang revealed that the funding will be used to drive product development at AND in fields such as sports medicine and artificial joints, including strengthening the talent pool, initiating projects, conducting clinical trials, procuring production and inspection equipment for implants, and expanding market presence.
Shi Shenghao, Managing Director of Sinopharm Capital, stated, “The trend of population aging has created substantial growth opportunities in the market for degenerative orthopedic diseases. The company has achieved remarkable results in both product portfolio development and channel construction, securing a leading market share in certain niche segments. Sinopharm Capital will further support the company’s development into an industry leader in orthopedics by providing assistance across three key dimensions: R&D, marketing, and capital.”
According to VCBeat, AND’s inclusion in the Sinopharm Capital FAMILY will enable it to forge a powerful alliance with the Sinopharm ecosystem’s resources, driving the company’s rapid growth in its next phase.
About AND
Suzhou AND Science and Technology Development Corp., established in 2006, is an integrated surgical solutions provider specializing in the research and development, manufacturing, sales, and professional technical services of orthopedic medical devices. With over a decade of focus on high-value orthopedic consumables, the company has maintained steady and efficient growth. Its production base is located in the Metallurgical Industrial Park of Zhangjiagang City. As of 2018, the company’s core products ranked among the leading domestic brands in their respective market segments.
About Sinopharm Capital
Sinopharm Capital Management Co., Ltd. was established in 2012 as a professional equity investment institution focused on the healthcare and wellness sector, initiated by China National Pharmaceutical Group (Sinopharm). Its management team comprises internal and external investment professionals from Sinopharm, operating under market-oriented mechanisms. With profound insights into the development, industrial operations, and capital management of the pharmaceutical and healthcare industry, the company effectively integrates industrial resources and capital strengths both within and outside Sinopharm.